Product Description
Bapineuzumab is a humanized form of murine monoclonal antibody 3D6, which targets the N-terminal region of Abeta. (Sourced from: https://www.alzforum.org/therapeutics/bapineuzumab)
Mechanisms of Action: AB Degrader
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: Johnson & Johnson
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| RAPID | N/A |
Terminated |
Alzheimer Disease |
2012-08-01 |
2019-03-19 |
Treatments |
|
| 3133K1-102 | P1 |
Completed |
Alzheimer Disease |
2010-02-01 |
2019-03-21 |
||
| SUMMIT AD | P2 |
Completed |
Alzheimer Disease |
2013-01-01 |
2019-03-19 |
Treatments |
|
| 3133L1-2204 | P2 |
Terminated |
Alzheimer Disease |
2012-09-01 |
2019-03-18 |
Treatments |
|
| AAB-001-251 | P2 |
Terminated |
Alzheimer Disease |
2012-09-01 |
2019-03-18 |
Treatments |
|
| 3133L1-2203 | P2 |
Completed |
Alzheimer Disease |
2010-10-01 |
2024-06-26 |
||
| 2004-004120-12 | P2 |
Completed |
Alzheimer Disease |
2009-11-12 |
2022-03-12 |
Treatments |
|
| 2006-004675-35 | P2 |
Terminated |
Alzheimer Disease |
2009-08-06 |
2022-03-12 |
Treatments |
|
| AAB-001-201 | P2 |
Completed |
Alzheimer Disease |
2008-11-01 |
2019-03-21 |
Treatments |
|
| PRI#585 | P2 |
Unknown status |
Alzheimer Disease |
None |
2019-03-21 |
Treatments |
|
| 2009-015079-29 | P3 |
Completed |
Alzheimer Disease |
2012-10-25 |
2022-03-13 |
Treatments |
|
| 2011-002133-20 | P3 |
Completed |
Alzheimer Disease |
2015-07-13 |
2022-03-13 |
Treatments |
|
| 3133K1-3002 | P3 |
Terminated |
Alzheimer Disease |
2012-11-01 |
2019-03-19 |
Treatments |
|
| 2009-015080-13 | P3 |
Completed |
Alzheimer Disease |
2012-10-16 |
2022-03-13 |
Treatments |
|
| 3133K1-3001 | P3 |
Terminated |
Alzheimer Disease |
2012-10-01 |
2024-06-26 |
||
| 3133K1-3000 | P3 |
Terminated |
Alzheimer Disease |
2012-10-01 |
2019-03-18 |
Treatments |
|
| 3133K1-3003 | P3 |
Terminated |
Alzheimer Disease |
2012-10-01 |
2019-03-19 |
Treatments |
|
| ELN115727-351 | P3 |
Terminated |
Alzheimer Disease |
2012-09-01 |
2019-03-18 |
Treatments |
|
| 2007-005995-14 | P3 |
Completed |
Alzheimer Disease |
2012-08-06 |
2025-07-09 |
Treatments |
|
| 2007-005994-79 | P3 |
Terminated |
Alzheimer Disease |
2012-08-06 |
2022-03-12 |
Treatments |
|
| 2009-012748-17 | P3 |
Completed |
Alzheimer Disease |
2012-06-05 |
2022-03-13 |
Treatments |
|
| ApoE4 Non-Carrier | P3 |
Completed |
Alzheimer Disease |
2012-06-01 |
2019-03-22 |
Treatments |
|
| ApoE4 Carrier | P3 |
Completed |
Alzheimer Disease |
2012-04-01 |
2019-03-22 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/13/2024 |
PubMed |
Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. |
|
05/07/2024 |
PubMed |
Passive immunotherapy for Alzheimer's disease: challenges & future directions. |
|
04/29/2024 |
PubMed |
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease. |
|
09/13/2021 |
News Article |
Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development |
|
03/04/2021 |
News Article |
Monoclonal Antibodies Market Report Examines Latest Trends and Key Drivers Supporting Growth |
|
09/28/2020 |
News Article |
Wren Therapeutics Announces Publication in Nature Research Journal |
|
01/07/2020 |
News Article |
Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning |